锶调控骨代谢机制的研究进展
Research Progress on the Mechanisms by Which Strontium Regulates Bone Metabolism
DOI: 10.12677/acm.2026.1631185, PDF, HTML, XML,   
作者: 熊缄琦, 刘雁鸣*:浙江大学医学院附属第二医院口腔颌面外科,浙江 杭州
关键词: 骨代谢钙离子敏感受体Bone Metabolism Strontium Calcium Ion-Sensitive Receptor
摘要: 锶作为一种与钙在化学性质上高度相似的元素,在骨代谢调控和骨修复过程中表现出显著的促成骨和抑制骨吸收作用,已被广泛应用于抗骨质疏松治疗及骨组织工程材料的设计中。然而,锶调控骨代谢的分子机制复杂,涉及MAPK/ERK、PI3K/Akt、Wnt和NFATc1等多条信号通路,并且通路之间存在相互影响,本文总结了近年来关于锶调控骨代谢机制的研究。
Abstract: Strontium, an element highly similar to calcium in chemical properties, exhibits significant osteogenic and osteoresorption-inhibiting effects in bone metabolism regulation and bone repair, and has been widely used in osteoporosis treatment and the design of bone tissue engineering materials. However, the molecular mechanisms by which strontium regulates bone metabolism are complex, involving multiple signaling pathways such as MAPK/ERK, PI3K/Akt, Wnt, and NFATc1, and these pathways interact with each other. This article summarizes recent research on the mechanisms by which strontium regulates bone metabolism.
文章引用:熊缄琦, 刘雁鸣. 锶调控骨代谢机制的研究进展[J]. 临床医学进展, 2026, 16(3): 3770-3776. https://doi.org/10.12677/acm.2026.1631185

1. 引言

在骨组织工程中,局部递送成骨活性因子是有效修复骨缺损的常用策略[1]-[3]。以骨形态发生蛋白-2 (Bone Morphogenetic Protein-2, BMP-2)为代表的多肽在骨修复中体现出了良好的成骨效果,但是其高成本,活性不稳定及异位成骨的风险在一定程度上限制了其临床应用[4]。近年来,金属离子因为稳定性高、作用持久且易于通过材料体系实现可控递送等优势而受到广泛关注[5] [6]。其中,锶离子作为一种具有成骨活性的二价阳离子,不仅能够促进成骨细胞分化,还可抑制破骨细胞活性,在骨代谢调控中展现出独特的双向调节作用[7] [8]。然而,锶调控骨代谢的机制复杂且未完全阐明,尽管已有研究对相关机制进行了总结,但针对相关通路的整合分析及通路间交叉机制的系统梳理仍相对不足。本文就锶的特点及其在骨代谢中的作用机制研究进展做一综述,重点对其在骨代谢中的相关信号通路和通路之间的相互作用进行总结和讨论。

2. 锶的生物学特性

锶位于元素周期表的第4周期,第IIA族,属于碱土金属元素。在人体内,锶主要以二价阳离子的形式存在,高度富集于骨骼和牙齿中[9]。由于锶的离子半径和钙离子相似,其能够在一定程度上替代钙离子参与骨基质矿化过程,并通过钙敏感受体(Calcium Ion-Sensitive Receptor, CaSR)介导的信号通路调控骨代谢[10]。早在20世纪中期,研究者即通过动物实验证明锶对骨代谢具有双向调控作用,且具有剂量依赖性[11]。在适宜浓度范围内,锶不仅可以促进成骨细胞的增殖、分化及基质矿化,还可以抑制破骨细胞的分化和骨吸收,而过高剂量的锶则可能干扰钙的代谢和矿物沉积,从而影响骨矿化过程[12]-[14]。随着含锶生物材料的不断发展和应用,研究表明锶还具有一定的免疫调节作用,能通过改善骨缺损局部微环境促进骨修复[15]。基于锶在骨代谢中的多重生物学效应,研究者从细胞水平和分子层面深入探讨了锶调控骨代谢的作用细胞及其相关信号通路。

3. 锶调控骨代谢的相关信号通路

作为一种在化学性质和离子半径上与Ca2+相似的二价阳离子,Sr2+被认为可作用于部分与Ca2+相同或相似的细胞靶点。因此,Ca2+敏感性信号通路被认为是介导Sr2+生物学效应的重要途径[10]。CaSR能够感知细胞外Ca2+及多种其他二价阳离子浓度变化,并将其转化为细胞内信号级联反应[16]。已有研究证明Sr2+可以与CaSR结合并激活Ca2+敏感通路如MAPK/ERK、PI3K/Akt和NFATc1,从而产生成骨效应[17]。此外,多条在骨稳态和骨重塑过程中发挥重要调控作用的信号通路,包括Wnt信号通路、RANK/RANKL/OPG系统以及成纤维细胞生长因子(FGF)/FGF受体信号通路,同样被报道与Sr2+的成骨效应密切相关[8]。并且,上述通路并非孤立存在,其可能相互影响,相关机制将在下文中进一步综述。

3.1. CaSR的结构和功能

CaSR是一种典型的G蛋白偶联受体,主要表达于间充质干细胞、成骨细胞及破骨细胞等细胞的细胞膜上[18] [19]。CaSR由胞外结构域、七次跨膜结构域及胞内结构域构成,其中,较大的胞外结构域负责感知细胞外Ca2+及其他二价阳离子的浓度变化,是CaSR行使生物学功能的关键结构基础[18] [19]

在多数细胞类型中,当细胞外Ca2+浓度升高时,Ca2+可与CaSR结合并激活CaSR。CaSR激活后通常通过偶联Gαq/11蛋白激活磷脂酶C (Phospholipase C, PLC),促使磷脂酰肌醇二磷酸(PIP2)水解生成三磷酸肌醇(IP3)和二酰甘油(DAG),IP3则可进一步诱导内质网Ca2+释放,从而激活多种Ca2+依赖性信号分子和转录调控机制[20]

3.2. 丝裂原活化蛋白激酶(MAPK)/ERK通路和磷脂酰肌醇3-激酶(PI3K)/Akt通路

MAPK/ERK和PI3K/Akt是细胞内较为经典且高度保守的两条信号转导通路,在细胞增殖、存活、分化及应激反应等过程中发挥核心调控作用[21] [22]。大鼠肉瘤蛋白(Rat Sarcomaviral Oncogene, Ras)是MAPK/ERK和PI3K/Akt共同的上游调控因子,在CaSR被激活后,Ras可由GDP结合状态转变为GTP结合状态(Ras-GTP),并启动下游通路的激活[23]。在MAPK/ERK通路中,Ras-GTP招募并激活RAF激酶,继而磷酸化并激活MEK1/2,随后ERK1/2被磷酸化并转位入核,调控Runx2、Osterix等成骨相关转录因子,从而促进成骨前体细胞的增殖与早期分化[24]。与此同时,Ras-GTP还可直接激活PI3K,催化PIP2转化为PIP3,招募并激活Akt,进而调控下游GSK-3β/β-catenin和mTOR等信号,从而增强成骨细胞存活、代谢活性及基质矿化能力[25]

已有实验证明,锶可以激活间充质干细胞中的Ras,并使ERK1/2和p38的磷酸化水平升高,从而提高Runx2的表达并促进间充质干细胞的成骨分化[24]。此外,研究者还发现聚多巴胺辅助的锶取代羟基磷灰石涂层有效激活了小鼠原代成骨细胞中的ERK/MAPK和PI3K/AKT信号通路,并提高了ALP活性和成骨基因的表达[26]。值得注意的是,相比于ERK1/2-MAPK通路,PI3K/Akt通路对成骨的调控并不完全依赖于CaSR的活化。Fromigué等人研究发现,锶在CaSR缺失(CaSR−/−)和正常(CaSR+/+)小鼠原代成骨细胞中都能促进Akt的磷酸化,而ERK1/2的激活只在CaSR+/+细胞中明显,提示锶激活PI3K/Akt信号可能部分独立于CaSR的存在[17]

3.3. Wnt信号通路

Wnt信号通路是调控骨形成与骨稳态维持的关键信号网络之一,根据是否依赖β-catenin介导的转录调控,Wnt通路传统上分为经典(Canonical)和非经典(Non-Canonical)两大类[27]

在经典Wnt/β-catenin通路中,Wnt配体与细胞膜上的Frizzled受体及低密度脂蛋白受体相关蛋白5/6 (Low-Density Lipoprotein Receptor-Related Protein 5/6, LRP5/6)共受体结合后,可抑制由GSK-3β、Axin和APC组成的β-catenin降解复合体,促进β-catenin在胞质中稳定积累并转位入核,从而上调Runx2、Osterix等成骨相关转录因子的表达,促进间充质干细胞向成骨谱系分化,并增强成骨细胞的成熟与矿化能力[28]。Rybchyn等人的研究表明,锶离子可以与CaSR结合并激活PI3K/Akt信号通路,活化后的Akt可抑制GSK-3β的活性,从而增强β-catenin在胞质中的稳定性[29]。该过程并非直接启动经典Wnt信号,而是通过调控β-catenin稳定性与经典Wnt/β-catenin通路在关键节点上形成协同作用,共同增强其促成骨效应。

非经典Wnt通路主要包括平面细胞极性(Planar Cell Polarity, PCP)通路和Wnt/Ca2+通路,其激活往往依赖于非经典Wnt配体(如Wnt5a)与Frizzled受体及ROR1/2、RYK等共受体的配合[30]。Zuzana Saidak等人的研究证实,锶可以增加小鼠成骨细胞中Wnt5a的表达[8]。Fromigué等人则证实抑制Wnt5a受体RYK能部分阻断Sr2+诱导的细胞增殖和成骨细胞基因表达[17]。然而,需要指出的是,现有研究多集中于锶诱导Wnt5a表达变化及其生物学效应的相关性,尚缺乏直接证据证明锶可作为非经典Wnt通路的特异性上游激活因子。另外,鉴于锶可通过激活CaSR诱导胞内Ca2+信号及下游Ca2+依赖性通路的激活,锶可能会通过CaSR介导的Ca2+信号与Wnt/Ca2+通路发生功能交叉,从而影响骨细胞行为和骨重塑过程。

3.4. RANK/RANKL/OPG途径

NF-κB受体激动剂(Receptor Activator of NF-κB, RANK)/RANKL/骨保护素(Osteoprotegerin, OPG)信号通路是调控破骨细胞分化、成熟及骨吸收过程的核心调控轴,在维持骨重塑动态平衡中发挥关键作用[31]。RANK主要表达于破骨细胞前体细胞表面,其配体RANKL主要由成骨细胞、骨髓基质细胞及成骨前体细胞分泌[32] [33]。RANKL与RANK结合后可促进破骨细胞的分化和骨吸收。然而,OPG可以通过与RANKL结合阻断其与RANK的相互作用,从而抑制破骨细胞生成,降低骨吸收水平[34] [35]

研究表明,锶可能可以通过CaSR依赖性的方式激活RANK/RANKL/OPG通路。T C Brennan等人发现敲低CaSR可抑制雷奈酸锶诱导的人原代成骨细胞OPG表达上调、RANKL下调以及细胞增殖,提示CaSR参与到了锶激活RANK/RANKL/OPG通路的过程中[10]。除此之外,锶也可通过CaSR非依赖性机制直接降低RANKL表达,从而抑制破骨细胞分化[17]。同时,锶可能通过激活经典Wnt/β-catenin通路间接影响RANK/RANKL/OPG通路,从而调控骨代谢。研究发现,锶可以增强MC3T3-E1细胞中LRP6/β-catenin/OPG信号通路,从而抑制破骨细胞分化[36]。但也有研究表明,在成骨样细胞中,Wnt/β-catenin信号通路的激活虽然显著提高了ALP活性和骨钙素表达水平,但对OPG的表达影响较小。这表明在不同细胞类型和实验条件下,Wnt/β-catenin信号通路的激活对RANK/RANKL/OPG的影响有所差异[37]

3.5. NFATc1通路

NFATc1 (Nuclear Factor of Activated T‑Cells, Cytoplasmic 1)属于NFAT家族成员,在成骨细胞和破骨细胞中发挥重要作用,也是多种细胞类型发育与免疫反应中的重要下游效应分子[38] [39]

研究表明,在成骨细胞中,锶可以激活NFATc1上调成骨相关基因COL1A1的表达[40]。在破骨细胞中,NFATc1经典的激活机制主要依赖于RANKL/RANK介导的Ca2+信号改变[41]。RANK与RANKL结合后可刺激PLC产生IP3,引发内质网Ca2+释放,进而导致NFATc1的激活[42] [43]。但目前尚无明确实验数据表明锶通过抑制破骨细胞表面的RANK表达影响Ca2+释放及NFATc1激活。然而,研究已证实锶能通过调节成骨细胞和基质中RANKL与OPG的表达,从而减弱RANK的活化信号[10]。鉴于RANKL/RANK信号是引发破骨细胞内Ca2+释放的关键上游事件,这种间接调控有助于理解Sr2+抑制破骨分化的分子机制。

3.6. 其他通路

除了上述途径之外,FGF/FGFR通路和Smad通路也被证明和锶调控骨代谢有关[8]。研究表明,雷奈酸锶可以通过FGF/FGFR通路激活多种细胞内通路,包括PI3K/Akt和ERK1/2等,而FGFR抑制剂可抑制雷奈酸锶诱导的MC3T3-E1细胞和原代成骨细胞的生长[44] [45]。此外,锶还可以通过增强BMP/Smad信号通路,促进Smad1/5/8磷酸化及核转位,上调Runx2等成骨相关转录因子的表达,从而促进成骨细胞分化与骨形成[46]

4. 总结

锶促成骨与抑制骨吸收的生物学效应并非依赖于单一信号轴,而是通过多条信号通路组成的信号网络实现。其中,CaSR在多条关键信号通路的激活中发挥了核心枢纽作用。锶可通过CaSR介导的Ras-MAPK/ERK和PI3K/Akt直接调控成骨细胞的增殖、生存及分化过程;与此同时,其还可通过影响β-catenin稳定性、调节Wnt信号强度,与经典Wnt/β-catenin通路在关键节点形成协同效应,从而进一步放大促成骨信号。在骨吸收调控方面,锶通过调节成骨细胞来源的RANKL与OPG表达比例,抑制破骨细胞分化和活性。此外,锶对NFATc1信号的影响更多体现为对上游Ca2+信号和RANKL/RANK轴的间接调控,从而削弱破骨细胞内NFATc1的激活。FGF/FGFR和BMP/Smad等信号通路同样参与了锶介导的成骨调控过程,并形成了动态交互的调控网络。但是,锶如何激活NFATc1及CaSR依赖性与非依赖性机制的界限仍有待进一步系统阐明。对这些问题的深入探索,将为锶基生物材料的开发设计提供更加坚实的理论基础。

NOTES

*通讯作者。

参考文献

[1] Szwed-Georgiou, A., Płociński, P., Kupikowska-Stobba, B., Urbaniak, M.M., Rusek-Wala, P., Szustakiewicz, K., et al. (2023) Bioactive Materials for Bone Regeneration: Biomolecules and Delivery Systems. ACS Biomaterials Science & Engineering, 9, 5222-5254. [Google Scholar] [CrossRef] [PubMed]
[2] Safari, B., Davaran, S. and Aghanejad, A. (2021) Osteogenic Potential of the Growth Factors and Bioactive Molecules in Bone Regeneration. International Journal of Biological Macromolecules, 175, 544-557. [Google Scholar] [CrossRef] [PubMed]
[3] Yuan, Z., Wei, P., Huang, Y., Zhang, W., Chen, F., Zhang, X., et al. (2019) Injectable PLGA Microspheres with Tunable Magnesium Ion Release for Promoting Bone Regeneration. Acta Biomaterialia, 85, 294-309. [Google Scholar] [CrossRef] [PubMed]
[4] James, A.W., LaChaud, G., Shen, J., Asatrian, G., Nguyen, V., Zhang, X., et al. (2016) A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2. Tissue Engineering Part B: Reviews, 22, 284-297. [Google Scholar] [CrossRef] [PubMed]
[5] Matic, T., Daou, F., Cochis, A., Barac, N., Ugrinovic, V., Rimondini, L., et al. (2024) Multifunctional Sr, Mg-Doped Mesoporous Bioactive Glass Nanoparticles for Simultaneous Bone Regeneration and Drug Delivery. International Journal of Molecular Sciences, 25, Article 8066. [Google Scholar] [CrossRef] [PubMed]
[6] Wu, C. and Chang, J. (2014) Multifunctional Mesoporous Bioactive Glasses for Effective Delivery of Therapeutic Ions and Drug/Growth Factors. Journal of Controlled Release, 193, 282-295. [Google Scholar] [CrossRef] [PubMed]
[7] Wang, L., Jiang, S., Zhou, J., Gholipourmalekabadi, M., Cao, Y., Lin, K., et al. (2025) From Hard Tissues to beyond: Progress and Challenges of Strontium-Containing Biomaterials in Regenerative Medicine Applications. Bioactive Materials, 49, 85-120. [Google Scholar] [CrossRef] [PubMed]
[8] Saidak, Z. and Marie, P.J. (2012) Strontium Signaling: Molecular Mechanisms and Therapeutic Implications in Osteoporosis. Pharmacology & Therapeutics, 136, 216-226. [Google Scholar] [CrossRef] [PubMed]
[9] Dahl, S.G., Allain, P., Marie, P.J., Mauras, Y., Boivin, G., Ammann, P., et al. (2001) Incorporation and Distribution of Strontium in Bone. Bone, 28, 446-453. [Google Scholar] [CrossRef] [PubMed]
[10] Brennan, T., Rybchyn, M., Green, W., Atwa, S., Conigrave, A. and Mason, R. (2009) Osteoblasts Play Key Roles in the Mechanisms of Action of Strontium Ranelate. British Journal of Pharmacology, 157, 1291-1300. [Google Scholar] [CrossRef] [PubMed]
[11] Storey, E. (1961) Strontium “Rickets”: Bone, Calcium and Strontium Changes. Australasian Annals of Medicine, 10, 213-222. [Google Scholar] [CrossRef] [PubMed]
[12] Marie, P.J. (2006) Strontium Ranelate: A Physiological Approach for Optimizing Bone Formation and Resorption. Bone, 38, 10-14. [Google Scholar] [CrossRef] [PubMed]
[13] Quade, M., Vater, C., Schlootz, S., Bolte, J., Langanke, R., Bretschneider, H., et al. (2019) Strontium Enhances BMP-2 Mediated Bone Regeneration in a Femoral Murine Bone Defect Model. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 108, 174-182. [Google Scholar] [CrossRef] [PubMed]
[14] Bonnelye, E., Chabadel, A., Saltel, F. and Jurdic, P. (2008) Dual Effect of Strontium Ranelate: Stimulation of Osteoblast Differentiation and Inhibition of Osteoclast Formation and Resorption in Vitro. Bone, 42, 129-138. [Google Scholar] [CrossRef] [PubMed]
[15] Miao, Q., Yang, X., Diao, J., Ding, H., Wu, Y., Ren, X., et al. (2023) 3D Printed Strontium-Doped Calcium Phosphate Ceramic Scaffold Enhances Early Angiogenesis and Promotes Bone Repair through the Regulation of Macrophage Polarization. Materials Today Bio, 23, Article 100871. [Google Scholar] [CrossRef] [PubMed]
[16] Goltzman, D. and Hendy, G.N. (2015) The Calcium-Sensing Receptor in Bone—Mechanistic and Therapeutic Insights. Nature Reviews Endocrinology, 11, 298-307. [Google Scholar] [CrossRef] [PubMed]
[17] Fromigué, O., Haÿ, E., Barbara, A., Petrel, C., Traiffort, E., Ruat, M., et al. (2009) Calcium Sensing Receptor-Dependent and Receptor-Independent Activation of Osteoblast Replication and Survival by Strontium Ranelate. Journal of Cellular and Molecular Medicine, 13, 2189-2199. [Google Scholar] [CrossRef] [PubMed]
[18] Kniazeff, J., Prézeau, L., Rondard, P., Pin, J. and Goudet, C. (2011) Dimers and Beyond: The Functional Puzzles of Class C GPCRs. Pharmacology & Therapeutics, 130, 9-25. [Google Scholar] [CrossRef] [PubMed]
[19] Hannan, F.M., Kallay, E., Chang, W., Brandi, M.L. and Thakker, R.V. (2018) The Calcium-Sensing Receptor in Physiology and in Calcitropic and Noncalcitropic Diseases. Nature Reviews Endocrinology, 15, 33-51. [Google Scholar] [CrossRef] [PubMed]
[20] Brown, E.M. and MacLeod, R.J. (2001) Extracellular Calcium Sensing and Extracellular Calcium Signaling. Physiological Reviews, 81, 239-297. [Google Scholar] [CrossRef] [PubMed]
[21] Johnson, G.L. and Lapadat, R. (2002) Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and P38 Protein Kinases. Science, 298, 1911-1912. [Google Scholar] [CrossRef] [PubMed]
[22] Manning, B.D. and Cantley, L.C. (2007) AKT/PKB Signaling: Navigating Downstream. Cell, 129, 1261-1274. [Google Scholar] [CrossRef] [PubMed]
[23] Aksamitiene, E., Kiyatkin, A. and Kholodenko, B.N. (2012) Cross-Talk between Mitogenic Ras/MAPK and Survival PI3K/Akt Pathways: A Fine Balance. Biochemical Society Transactions, 40, 139-146. [Google Scholar] [CrossRef] [PubMed]
[24] Peng, S., Zhou, G., Luk, K.D.K., Cheung, K.M.C., Li, Z., Lam, W.M., et al. (2009) Strontium Promotes Osteogenic Differentiation of Mesenchymal Stem Cells through the Ras/MAPK Signaling Pathway. Cellular Physiology and Biochemistry, 23, 165-174. [Google Scholar] [CrossRef] [PubMed]
[25] Papaioannou, G., Mirzamohammadi, F. and Kobayashi, T. (2016) Ras Signaling Regulates Osteoprogenitor Cell Proliferation and Bone Formation. Cell Death & Disease, 7, e2405. [Google Scholar] [CrossRef] [PubMed]
[26] Sun, Y., Li, Y., Zhang, Y., Wang, T., Lin, K. and Liu, J. (2021) A Polydopamine-Assisted Strontium-Substituted Apatite Coating for Titanium Promotes Osteogenesis and Angiogenesis via FAK/MAPK and PI3K/AKT Signaling Pathways. Materials Science and Engineering: C, 131, Article 112482. [Google Scholar] [CrossRef] [PubMed]
[27] Baron, R. and Kneissel, M. (2013) WNT Signaling in Bone Homeostasis and Disease: From Human Mutations to Treatments. Nature Medicine, 19, 179-192. [Google Scholar] [CrossRef] [PubMed]
[28] Krishnan, V., Bryant, H.U. and Macdougald, O.A. (2006) Regulation of Bone Mass by Wnt Signaling. Journal of Clinical Investigation, 116, 1202-1209. [Google Scholar] [CrossRef] [PubMed]
[29] Rybchyn, M.S., Slater, M., Conigrave, A.D. and Mason, R.S. (2011) An Akt-Dependent Increase in Canonical Wnt Signaling and a Decrease in Sclerostin Protein Levels Are Involved in Strontium Ranelate-Induced Osteogenic Effects in Human Osteoblasts. Journal of Biological Chemistry, 286, 23771-23779. [Google Scholar] [CrossRef] [PubMed]
[30] van Amerongen, R. and Nusse, R. (2009) Towards an Integrated View of Wnt Signaling in Development. Development, 136, 3205-3214. [Google Scholar] [CrossRef] [PubMed]
[31] Wada, T., Nakashima, T., Hiroshi, N. and Penninger, J.M. (2006) RANKL-RANK Signaling in Osteoclastogenesis and Bone Disease. Trends in Molecular Medicine, 12, 17-25. [Google Scholar] [CrossRef] [PubMed]
[32] Lacey, D.L., Timms, E., Tan, H.L., Kelley, M.J., Dunstan, C.R., Burgess, T., et al. (1998) Osteoprotegerin Ligand Is a Cytokine That Regulates Osteoclast Differentiation and Activation. Cell, 93, 165-176. [Google Scholar] [CrossRef] [PubMed]
[33] Kong, Y., Yoshida, H., Sarosi, I., Tan, H., Timms, E., Capparelli, C., et al. (1999) OPGL Is a Key Regulator of Osteoclastogenesis, Lymphocyte Development and Lymph-Node Organogenesis. Nature, 397, 315-323. [Google Scholar] [CrossRef] [PubMed]
[34] Simonet, W.S., Lacey, D.L., Dunstan, C.R., Kelley, M., et al. (1997) Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density. Cell, 89, 309-319. [Google Scholar] [CrossRef] [PubMed]
[35] Hofbauer, L.C. and Heufelder, A.E. (2001) Role of Receptor Activator of Nuclear Factor-κB Ligand and Osteoprotegerin in Bone Cell Biology. Journal of Molecular Medicine, 79, 243-253. [Google Scholar] [CrossRef] [PubMed]
[36] Sun, T., Li, Z., Zhong, X., Cai, Z., Ning, Z., Hou, T., et al. (2019) Strontium Inhibits Osteoclastogenesis by Enhancing LRP6 and β-Catenin-Mediated OPG Targeted by miR-181d-5p. Journal of Cell Communication and Signaling, 13, 85-97. [Google Scholar] [CrossRef] [PubMed]
[37] Nie, B., Zhang, S.Y., Guan, S.M., Zhou, S.Q. and Fang, X. (2019) Role of Wnt/β-Catenin Pathway in the Arterial Medial Calcification and Its Effect on the OPG/RANKL System. Current Medical Science, 39, 28-36. [Google Scholar] [CrossRef] [PubMed]
[38] TAkayanagi, H. (2007) The Role of NFAT in Osteoclast Formation. Annals of the New York Academy of Sciences, 1116, 227-237. [Google Scholar] [CrossRef] [PubMed]
[39] Crabtree, G.R. and Olson, E.N. (2002) NFAT Signaling. Cell, 109, S67-S79. [Google Scholar] [CrossRef] [PubMed]
[40] Fromigué, O., Haÿ, E., Barbara, A. and Marie, P.J. (2010) Essential Role of Nuclear Factor of Activated T Cells (NFAT)-Mediated Wnt Signaling in Osteoblast Differentiation Induced by Strontium Ranelate. Journal of Biological Chemistry, 285, 25251-25258. [Google Scholar] [CrossRef] [PubMed]
[41] Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., et al. (2002) Induction and Activation of the Transcription Factor Nfatc1 (NFAT2) Integrate RANKL Signaling in Terminal Differentiation of Osteoclasts. Developmental Cell, 3, 889-901. [Google Scholar] [CrossRef] [PubMed]
[42] Koga, T., Inui, M., Inoue, K., Kim, S., Suematsu, A., Kobayashi, E., et al. (2004) Costimulatory Signals Mediated by the ITAM Motif Cooperate with RANKL for Bone Homeostasis. Nature, 428, 758-763. [Google Scholar] [CrossRef] [PubMed]
[43] Hogan, P.G., Chen, L., Nardone, J. and Rao, A. (2003) Transcriptional Regulation by Calcium, Calcineurin, and NFAT. Genes & Development, 17, 2205-2232. [Google Scholar] [CrossRef] [PubMed]
[44] Caverzasio, J. (2008) Strontium Ranelate Promotes Osteoblastic Cell Replication through at Least Two Different Mechanisms. Bone, 42, 1131-1136. [Google Scholar] [CrossRef] [PubMed]
[45] Caverzasio, J. and Thouverey, C. (2011) Activation of FGF Receptors Is a New Mechanism by Which Strontium Ranelate Induces Osteoblastic Cell Growth. Cellular Physiology and Biochemistry, 27, 243-250. [Google Scholar] [CrossRef] [PubMed]
[46] Lv, H., Huang, X., Jin, S., Guo, R. and Wu, W. (2013) Strontium Ranelate Promotes Osteogenic Differentiation of Rat Bone Mesenchymal Stem Cells through Bone Morphogenetic Protein-2/Smad Signaling Pathway. Journal of Southern Medical University, 33, 376-381.